Erythropoietin and mesenchymal stromal cells in angiogenesis and myocardial regeneration: One plus one equals three?

Cardiovascular Research

Volumn 79, Issue 3, 2008, Pages 357-359

  Ward, Michael R ^a   Stewart, Duncan J ^a  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENOMEDULLIN; ERYTHROPOIETIN;

ANGIOGENESIS; AUTOCRINE EFFECT; DISEASE MODEL; EDITORIAL; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE; HEART PERFUSION; HUMAN; LIMB ISCHEMIA; MESENCHYME CELL; MUSCLE REGENERATION; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN SECRETION; STROMA CELL;

ANIMALS; AUTOCRINE COMMUNICATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; DISEASE MODELS, ANIMAL; ERYTHROPOIETIN; GENE THERAPY; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIUM; NEOVASCULARIZATION, PHYSIOLOGIC; PARACRINE COMMUNICATION; REGENERATION; STROMAL CELLS; VENTRICULAR FUNCTION, LEFT;

EID: 48749105512     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvn153     Document Type: Editorial

References (39)

1. Abdel-Latif A, Bolli R, Tleyjeh IM, Montori VM, Perin EC, Hornung CA et al. Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. Arch Intern Med 2007;167:989-997.
2. Lipinski MJ, Biondi-Zoccai GG, Abbate A, Khianey R, Sheiban I, Bartunek J et al. Impact of intracoronary cell therapy on left ventricular function in the setting of acute myocardial infarction: a collaborative systematic review and meta-analysis of controlled clinical trials. J Am Coll Cardiol 2007;50:1761-1767.
3. Bartsch T, Brehm M, Zeus T, Kogler G, Wernet P, Strauer BE. Transplantation of autologous mononuclear bone marrow stem cells in patients with peripheral arterial disease (the TAM-PAD study). Clin Res Cardiol 2007;96:891-899.
4. Rissanen TT, Yla-Herttuala S. Current status of cardiovascular gene therapy. Mol Ther 2007;15:1233-1247.
5. Schachinger V, Erbs S, Elsasser A, Haberbosch W, Hambrecht R, Holschermann H et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 2006;355:1210-1221.
6. Tang YL, Zhao Q, Zhang YC, Cheng L, Liu M, Shi J et al. Autologous mesenchymal stem cell transplantation induce VEGF and neovascularization in ischemic myocardium. Regul Pept 2004;117:3-10.
7. Silva GV, Litovsky S, Assad JA, Sousa AL, Martin BJ, Vela D et al. Mesenchymal stem cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a canine chronic ischemia model. Circulation 2005;111:150-156.
8. Iwase T, Nagaya N, Fujii T, Itoh T, Murakami S, Matsumoto T et al. Comparison of angiogenic potency between mesenchymal stem cells and mononuclear cells in a rat model of hindlimb ischemia. Cardiovasc Res 2005;66:543-551.
9. Schafer R, Northoff H. Cardioprotection and cardiac regeneration by mesenchymal stem cells. Panminerva Med 2008;50:31-39.
10. Toma C, Pittenger MF, Cahill KS, Byrne BJ, Kessler PD. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation 2002;105:93-98.
11. Kinnaird T, Stabile E, Burnett MS, Lee CW, Barr S, Fuchs S et al. Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ Res 2004;94:678-685.
12. Iyer SS, Rojas M. Anti-inflammatory effects of mesenchymal stem cells: novel concept for future therapies. Expert Opin Biol Ther 2008;8:569-581.
13. Li L, Zhang S, Zhang Y, Yu B, Xu Y, Guan Z. Paracrine action mediate the antifibrotic effect of transplanted mesenchymal stem cells in a rat model of global heart failure. Mol Biol Rep 2008; March 27 [Epub ahead of print].
14. Zhang W, Qin C, Zhou ZM. Mesenchymal stem cells modulate immune responses combined with cyclosporine in a rat renal transplantation model. Transplant Proc 2007;39:3404-3408.
15. De Kok IJ, Peter SJ, Archambault M, van den Bos C, Kadiyala S, Aukhil I et al. Investigation of allogeneic mesenchymal stem cell-based alveolar bone formation: preliminary findings. Clin Oral Implants Res 2003;14:481-489.
16. Taupin P. OTI-010 Osiris therapeutics/JCR pharmaceuticals. Curr Opin Invest Drugs 2006;7:473-481.
17. Schuleri KH, Boyle AJ, Hare JM. Mesenchymal stem cells for cardiac regenerative therapy. Handb Exp Pharmacol 2007;180:195-218
18. Muller-Ehmsen J, Krausgrill B, Burst V, Schenk K, Neisen UC, Fries JW et al. Effective engraftment but poor mid-term persistence of mononuclear and mesenchymal bone marrow cells in acute and chronic rat myocardial infarction. J Mol Cell Cardiol 2006;41:876-884.
19. Gao F, He T, Wang H, Yu S, Yi D, Liu W et al. A promising strategy for the treatment of ischemic heart disease: mesenchymal stem cell-mediated vascular endothelial growth factor gene transfer in rats. Can J Cardiol 2007;23:891-898.
20. Zhou WW, Hu JG, Yang JF, Lin L, Zhou XM, Tang T. Angiogenic effect of bone marrow mesenchymal stem cells transfected with human VEGF gene on myocardial infarcts in rats. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2006;31:763-766, 771.
21. Wang Y, Haider HK, Ahmad N, Xu M, Ge R, Ashraf M. Combining pharmacological mobilization with intramyocardial delivery of bone marrow cells over-expressing VEGF is more effective for cardiac repair. J Mol Cell Cardiol 2006;40:736-745.
22. Mangi AA, Noiseux N, Kong D, He H, Rezvani M, Ingwall JS et al. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat Med 2003;9:1195-1201.
23. Burger D, Lei M, Geoghegan-Morphet N, Lu X, Xenocostas A, Feng Q. Erythropoietin protects cardiomyocytes from apoptosis via up-regulation of endothelial nitric oxide synthase. Cardiovasc Res 2006;72:51-59.
24. von Lindern M, Parren-van Amelsvoort M, van Dijk T, Deiner E, van den Akker E, van Emst-de Vries S et al. Protein kinase C alpha controls erythropoietin receptor signaling. J Biol Chem 2000;275:34719- 34727.
25. Mudalagiri NR, Mocanu MM, Di Salvo C, Kolvekar S, Hayward M, Yap J et al. Erythropoietin protects the human myocardium against hypoxia/reoxygenation injury via phosphatidylinositol-3 kinase and ERK1/2 activation. Br J Pharmacol 2008;153:50-56.
26. Lipsic E, Westenbrink BD, van der Meer P, van der Harst P, Voors AA, van Veldhuisen DJ et al. Low-dose erythropoietin improves cardiac function in experimental heart failure without increasing haematocrit. Eur J Heart Fail 2008;10:22-29.
27. Westenbrink BD, Voors AA, Ruifrok WP, van Gilst WH, van Veldhuisen DJ. Therapeutic potential of erythropoietin in cardiovascular disease: erythropoiesis and beyond. Curr Heart Fail Rep 2007;4:127-133.
28. Westenbrink BD, Lipsic E, van der Meer P, van der Harst P, Oeseburg H, Du Marchie Sarvaas GJ et al. Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization. Eur Heart J 2007;28:2018-2027.
29. Zhang D, Zhang F, Zhang Y, Gao X, Li C, Ma W et al. Erythropoietin enhances the angiogenic potency of autologous bone marrow stromal cells in a rat model of myocardial infarction. Cardiology 2007;108:228-236.
30. Copland IB, Jolicoeur EM, Gillis M-A, Cuerquis J, Eliopoulos N, Annabi B et al. Coupling erythropoietin secretion to mesenchymal stromal cells enhances their regenerative properties. Cardiovasc Res 2008; 79:405-415.
31. Roobrouck VD, Ulloa-Montoya F, Verfaillie CM. Self-renewal and differentiation capacity of young and aged stem cells. Exp Cell Res 2008;314:1937-1944.
32. Li YM, Schilling T, Benisch P, Zeck S, Meissner-Weigl J, Schneider D et al. Effects of high glucose on mesenchymal stem cell proliferation and differentiation. Biochem Biophys Res Commun 2007;363:209-215.
33. Murasawa S, Llevadot J, Silver M, Isner JM, Losordo DW, Asahara T. Constitutive human telomerase reverse transcriptase expression enhances regenerative properties of endothelial progenitor cells. Circulation 2002;106:1133-1139.
34. Kobune M, Kawano Y, Ito Y, Chiba H, Nakamura K, Tsuda H et al. Telomerized human multipotent mesenchymal cells can differentiate into hematopoietic and cobblestone area-supporting cells. Exp Hematol 2003;31:715-722.
35. Rajasingh J, Lambers E, Hamada H, Bord E, Thorne T, Goukassian I et al. Cell-free embryonic stem cell extract-mediated derivation of multipotent stem cells from NIH3T3 fibroblasts for functional and anatomical ischemic tissue repair. Circ Res 2008.
36. Stadtfeld M, Maherali N, Breault DT, Hochedlinger K. Defining molecular cornerstones during fibroblast to iPS cell reprogramming in mouse. Cell Stem Cell 2008;2:230-240.
37. Roche S, Richard MJ, Favrot MC. Oct-4, Rex-1, and Gata-4 expression in human MSC increase the differentiation efficiency but not hTERT expression. J Cell Biochem 2007;101:271-280.
38. Shima Y, Okamoto T, Aoyama T, Yasura K, Ishibe T, Nishijo K et al. In vitro transformation of mesenchymal stem cells by oncogenic H-rasVal12. Biochem Biophys Res Commun 2007;353:60-66.
39. Rubio D, Garcia S, De la Cueva T, Paz MF, Lloyd AC, Bernad A et al. Human mesenchymal stem cell transformation is associated with a mesenchymal-epithelial transition. Exp Cell Res 2008;314:691-698.